Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients.
Counseling
Diagnosis
Genetic testing
Hypertrophic cardiomyopathy
Next generation sequencing
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
05 03 2021
05 03 2021
Historique:
received:
24
05
2020
accepted:
22
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
5
10
2021
Statut:
epublish
Résumé
Genetic testing in hypertrophic cardiomyopathy (HCM) is a published guideline-based recommendation. The diagnostic yield of genetic testing and corresponding HCM-associated genes have been largely documented by single center studies and carefully selected patient cohorts. Our goal was to evaluate the diagnostic yield of genetic testing in a heterogeneous cohort of patients with a clinical suspicion of HCM, referred for genetic testing from multiple centers around the world. A retrospective review of patients with a suspected clinical diagnosis of HCM referred for genetic testing at Blueprint Genetics was undertaken. The analysis included syndromic, myopathic and metabolic etiologies. Genetic test results and variant classifications were extracted from the database. Variants classified as pathogenic (P) or likely pathogenic (LP) were considered diagnostic. A total of 1376 samples were analyzed. Three hundred and sixty-nine tests were diagnostic (26.8%); 373 P or LP variants were identified. Only one copy number variant was identified. The majority of diagnostic variants involved genes encoding the sarcomere (85.0%) followed by 4.3% of diagnostic variants identified in the RASopathy genes. Two percent of diagnostic variants were in genes associated with a cardiomyopathy other than HCM or an inherited arrhythmia. Clinical variables that increased the likelihood of identifying a diagnostic variant included: an earlier age at diagnosis (p < 0.0001), a higher maximum wall thickness (MWT) (p < 0.0001), a positive family history (p < 0.0001), the absence of hypertension (p = 0.0002), and the presence of an implantable cardioverter-defibrillator (ICD) (p = 0.0004). The diagnostic yield of genetic testing in this heterogeneous cohort of patients with a clinical suspicion of HCM is lower than what has been reported in well-characterized patient cohorts. We report the highest yield of diagnostic variants in the RASopathy genes identified in a laboratory cohort of HCM patients to date. The spectrum of genes implicated in this unselected cohort highlights the importance of pre-and post-test counseling when offering genetic testing to the broad HCM population.
Sections du résumé
BACKGROUND
Genetic testing in hypertrophic cardiomyopathy (HCM) is a published guideline-based recommendation. The diagnostic yield of genetic testing and corresponding HCM-associated genes have been largely documented by single center studies and carefully selected patient cohorts. Our goal was to evaluate the diagnostic yield of genetic testing in a heterogeneous cohort of patients with a clinical suspicion of HCM, referred for genetic testing from multiple centers around the world.
METHODS
A retrospective review of patients with a suspected clinical diagnosis of HCM referred for genetic testing at Blueprint Genetics was undertaken. The analysis included syndromic, myopathic and metabolic etiologies. Genetic test results and variant classifications were extracted from the database. Variants classified as pathogenic (P) or likely pathogenic (LP) were considered diagnostic.
RESULTS
A total of 1376 samples were analyzed. Three hundred and sixty-nine tests were diagnostic (26.8%); 373 P or LP variants were identified. Only one copy number variant was identified. The majority of diagnostic variants involved genes encoding the sarcomere (85.0%) followed by 4.3% of diagnostic variants identified in the RASopathy genes. Two percent of diagnostic variants were in genes associated with a cardiomyopathy other than HCM or an inherited arrhythmia. Clinical variables that increased the likelihood of identifying a diagnostic variant included: an earlier age at diagnosis (p < 0.0001), a higher maximum wall thickness (MWT) (p < 0.0001), a positive family history (p < 0.0001), the absence of hypertension (p = 0.0002), and the presence of an implantable cardioverter-defibrillator (ICD) (p = 0.0004).
CONCLUSION
The diagnostic yield of genetic testing in this heterogeneous cohort of patients with a clinical suspicion of HCM is lower than what has been reported in well-characterized patient cohorts. We report the highest yield of diagnostic variants in the RASopathy genes identified in a laboratory cohort of HCM patients to date. The spectrum of genes implicated in this unselected cohort highlights the importance of pre-and post-test counseling when offering genetic testing to the broad HCM population.
Identifiants
pubmed: 33673806
doi: 10.1186/s12872-021-01927-5
pii: 10.1186/s12872-021-01927-5
pmc: PMC7934228
doi:
Substances chimiques
Genetic Markers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Références
Hum Mutat. 2018 Jul;39(7):954-958
pubmed: 29696744
Clin Genet. 2003 Oct;64(4):339-49
pubmed: 12974739
J Prenat Med. 2014 Apr-Jun;8(3-4):57-69
pubmed: 26266003
Genet Med. 2017 Feb;19(2):192-203
pubmed: 27532257
Eur J Med Genet. 2010 Sep-Oct;53(5):261-7
pubmed: 20624503
Circ Cardiovasc Genet. 2017 Oct;10(5):
pubmed: 29030401
Am J Med Genet A. 2019 Apr;179(4):608-614
pubmed: 30762279
Genet Med. 2015 Nov;17(11):880-8
pubmed: 25611685
Mayo Clin Proc. 2005 Jun;80(6):739-44
pubmed: 15945527
J Am Coll Cardiol. 2012 Aug 21;60(8):705-15
pubmed: 22796258
Circ Cardiovasc Genet. 2017 Aug;10(4):
pubmed: 28790153
J Card Fail. 2018 May;24(5):281-302
pubmed: 29567486
Circ Cardiovasc Genet. 2013 Feb;6(1):19-26
pubmed: 23239831
PLoS One. 2017 Aug 3;12(8):e0181465
pubmed: 28771489
Genet Med. 2019 Feb;21(2):284-292
pubmed: 29875424
Genet Med. 2019 Jul;21(7):1576-1584
pubmed: 30531895
Nat Biotechnol. 2011 Oct 23;29(11):1024-7
pubmed: 22020387
PLoS One. 2018 Sep 20;13(9):e0203422
pubmed: 30235249
Nat Genet. 2019 Nov;51(11):1560-1565
pubmed: 31676867
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Am Coll Cardiol. 2018 Jul 24;72(4):419-429
pubmed: 30025578
J Cardiovasc Transl Res. 2014 Apr;7(3):347-61
pubmed: 24510615
Mol Genet Genomic Med. 2015 Dec 16;4(2):143-51
pubmed: 27066507
J Am Coll Cardiol. 2015 Mar 31;65(12):1249-1254
pubmed: 25814232
Circ Genom Precis Med. 2019 Feb;12(2):e002460
pubmed: 30681346
Circulation. 1995 Aug 15;92(4):785-9
pubmed: 7641357
Int J Mol Sci. 2016 Jul 30;17(8):
pubmed: 27483260
Hum Mutat. 2009 Mar;30(3):363-70
pubmed: 19035361
Mayo Clin Proc. 2014 Jun;89(6):727-37
pubmed: 24793961
Circ Cardiovasc Genet. 2017 Apr;10(2):
pubmed: 28408708
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338